登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：600062 证券简称：华润双鹤 公告编号：临2025－103 华润双鹤药业股份有限公司 关于变更注册资本的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 2025年12月2日公司第十届董事会第十五次会议审议通过《关于变更注册资本的议案》，具体情况如 下： 鉴于公司2021年限制性股票激励计划部分激励对象不符合激励条件，公司拟回购注销部分激励对象已获 授但尚未解除限售的限制性股票17.4998万股，导致公司股份总数、注册资本发生变化，公司股份总数 变更为103,858.2511万股，注册资本减少至103,858.2511万元。 上述变更注册资本事项需提交股东会审议批准。 特此公告。 华润双鹤药业股份有限公司 董 事 会 2025年12月4日 二、监事会会议审议情况 1、关于公司及经理层成员2024年业绩合同评价结果及薪酬分配的议案 结合公司2024年的业绩成绩及经理层成员的履职情况，同意公司及经理层成员2024年业绩合同评价结果 以及薪酬分配方案。 5票同意，0 ...

Group 1 - The company has developed a microbial protein that is efficient, sustainable, and free from antibiotics, featuring high protein, high dietary fiber, low sugar, low fat, and zero cholesterol characteristics [2] - The amino acid composition of the product closely matches human nutritional needs, and it is currently available for sale in major retail stores and online platforms [2] - The company announced that its microbial protein has recently received new food ingredient certification from the National Health Commission, and it is actively negotiating with downstream customers to promote the launch of end-consumer products [2]

Core Viewpoint - The company is actively advancing its Phase III clinical trial for GST-HG141, a key project in its innovative drug development pipeline, but has not scheduled a mid-term data unblinding analysis to ensure data integrity [1] Group 1 - The Phase III clinical trial for GST-HG141 is a 48-week randomized double-blind study [1] - The company is committed to efficiently progressing the trial and will disclose significant advancements in innovative drug development in a timely manner [1] - The company appreciates the support and interest from investors regarding the trial [1]

Group 1 - The core viewpoint of the article is that Jiuzhou Pharmaceutical is actively expanding its global market presence by establishing a wholly-owned subsidiary in Japan to invest in a CRO service platform, with positive business progress and growth in both clients and projects [1] Group 2 - The company plans to set up the subsidiary in early 2024 [1] - The business development is reported to be progressing smoothly, indicating a favorable operational environment [1] - There is a notable increase in both the number of clients and projects, reflecting strong demand and growth potential [1]

Core Viewpoint - Yuheng Pharmaceutical announced the investment of 210 million yuan in financial products from October 17, 2025, to December 3, 2025, utilizing idle funds [2] Group 1 - The company has recently invested 50 million yuan in the Xinyin Wealth Management's Anyingxiang Fixed Income Stable Income Closed-end Product No. 212 [2] - The investment period for the newly purchased financial product is 92 days, starting from December 3, 2025 [2] - The performance benchmark for the financial product ranges from 1.85% to 2.15% [2]

Core Viewpoint - The company, Xinlitai (002294.SZ), has received approval from the National Medical Products Administration for clinical trials of its innovative small molecule drug SAL0140, aimed at treating chronic kidney disease (CKD) [1] Group 1: Drug Development - SAL0140 is a proprietary aldosterone synthase inhibitor developed by the company, targeting conditions such as uncontrolled hypertension (including resistant hypertension), primary aldosteronism, and chronic kidney disease (CKD) [1] - The drug is expected to mitigate end-organ damage through the inhibition of aldosterone synthesis, potentially improving the progression of chronic kidney disease [1] Group 2: Mechanism of Action - Aldosterone is a crucial mineralocorticoid hormone that maintains fluid and electrolyte balance by activating mineralocorticoid receptors (MR), and it is directly involved in various cardiovascular and renal diseases [1] - Aldosterone synthase inhibitors may offer therapeutic benefits by reducing both genomic and non-genomic effects associated with end-organ damage [1]

Group 1 - Dongfang Electric announced that three executives plan to reduce their holdings by a total of no more than 30,000 shares due to personal financial needs [1] - Yahu Pharmaceutical's APL-1401 clinical trial data was presented at the 19th European Colorectal Congress, indicating progress in treating moderate to severe ulcerative colitis [1] - Guizhou Bai Ling's actual controller is under investigation by the China Securities Regulatory Commission for insider trading and information disclosure violations [3] Group 2 - Bairen Medical's ePTFE pericardial membrane product has been approved for registration, ending the reliance on imports for this product in the domestic market [4] - Qianxin received approval for a total of 2 billion yuan in technology innovation bonds, with plans to issue medium-term notes and short-term financing bonds [6] - Tengjing Technology's shareholder plans to reduce holdings by no more than 1.96% of the company's shares [7] Group 3 - Yuntianhua's subsidiary is required to pay 386 million yuan in overdue taxes and penalties, which will impact the company's net profit for 2025 [8] - Jianyou Pharmaceutical's propofol emulsion injection has received FDA approval in the United States [9] - Suzhou Gaoxin successfully acquired land use rights for a residential project for 360 million yuan [9] Group 4 - Chalco International's subsidiary won a bid for a 3.03 billion yuan electrolytic aluminum project [11] - Tai Long Pharmaceutical's stock will continue to be suspended due to potential changes in control as the major shareholder is planning a share transfer [12] - Qianli Technology reported a 63.44% year-on-year increase in automobile sales for November, although new energy vehicle sales decreased by 43.98% [13] Group 5 - Fosun Pharma's innovative drug FXS0887 has received approval for a Phase I clinical trial for advanced malignant solid tumors [14] - Guoen Co. has obtained approval for a project to produce 20,000 square meters of aviation-grade acrylic glass, with a total investment of 560 million yuan [15] - Guofa Co.'s chairman resigned due to personal reasons [17] Group 6 - Shanghai Construction won a bid for a state-owned construction land use right for 264 million yuan [18] - Weixin Kang's subsidiary received approval for a clinical trial of lidocaine cream for local anesthesia [20] - Sanxing Medical's subsidiary is a candidate for a 152 million yuan transformer procurement project for the State Grid [20] Group 7 - People's Daily announced the resignation of its president due to work changes, while retaining other leadership roles [21] - Beibu Gulf Port reported a 0.29% year-on-year increase in cargo throughput for November [22] - Chongqing Construction won three engineering projects with a total value of approximately 2.773 billion yuan [23] Group 8 - Xingyu Co. is planning to issue H-shares and list on the Hong Kong Stock Exchange [24] - Huajian Group signed a design contract worth 160 million yuan for a comprehensive project [25] - Wankai New Materials plans to invest 350 million yuan in a technical transformation project for producing 100,000 tons of adipic acid [26] Group 9 - Kaipuyun received a government subsidy of 18 million yuan, which is 87.43% of its net profit for the last audited fiscal year [28] - Ningbo Port expects a 10.8% year-on-year increase in container throughput for November [30] - An Cai High-Tech plans to invest 498 million yuan to upgrade its photovoltaic glass production line [32] Group 10 - Shunhao Co. stated that its existing business has not generated synergies with the rail business, which faces various risks [34] - Yihualu plans to publicly transfer 35% of its stake in Liaoyun Company [35] - ST Wanfang's shareholder plans to reduce holdings by no more than 3% of the company's shares [36] Group 11 - Youyou Food's shareholder plans to reduce holdings by no more than 110,000 shares [38] - Hengtong Optic-Electric's incentive fund has spent 49.98 million yuan to purchase company shares [41] - Zoli Pharmaceutical plans to issue convertible bonds to raise no more than 1.556 billion yuan for various projects [42]

Core Viewpoint - The company, Jianyou Co., Ltd. (健友股份), has received approval from the U.S. Food and Drug Administration (FDA) for its propofol emulsion injection, which is expected to positively impact the company's operating performance [1] Group 1 - The FDA has issued an ANDA approval notification for Jianyou's propofol emulsion injection in three specifications: 200mg/20mL, 500mg/50mL, and 1000mg/100mL [1] - The newly approved product is scheduled to be launched in the U.S. market soon [1] - The approval is anticipated to have a positive effect on the company's business performance [1]

Core Viewpoint - Weitengkang (603676) announced that its wholly-owned subsidiary, Tibet Zhongwei Chengkang Pharmaceutical Co., Ltd., received approval from the National Medical Products Administration for the clinical trial of Lidocaine Dincaine Cream for local anesthesia in adult skin surgeries [1] Group 1 - The approval allows the company to conduct clinical trials for the product, which is intended for local anesthesia on intact skin prior to surgical procedures [1]

Core Viewpoint - The company, Jianyou Co., Ltd. (603707.SH), has received ANDA approval from the U.S. FDA for its propofol emulsion injection in various dosages [1] Group 1 - The approved dosages include 200 mg/20 mL (10 mg/mL), 500 mg/50 mL (10 mg/mL), and 1,000 mg/100 mL (10 mg/mL) [1]